BioCentury
ARTICLE | Clinical News

Qnasl beclomethasone dipropionate nasal aerosol: Additional Phase III data

December 17, 2012 8:00 AM UTC

Additional data from a double-blind, U.S. Phase III trial in 529 patients ages 12 and older showed that there were no clinically important differences in intraocular pressure (IOP) between the once-daily 320 µg Qnasl and placebo arms during the 52-week treatment period. IOP remained within the normal range of <21 mmHg in 94% of patients treated with Qnasl. Additionally, Qnasl significantly reduced physician-assessed nasal symptom scores from baseline to week 30 (0.63 points, p=0.005) and to week 52 (0.6 points, p=0.008) vs. placebo. Data were presented at the American College of Allergy, Asthma and Immunology meeting in Anaheim. ...